Ind-Swift Limited (INDSWFTLTD.NS)
INR 13.38
(0.15%)
INR 13.38
(0.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.22 Billion INR | 33.65% |
| 2022 | 160.17 Million INR | -46.16% |
| 2021 | 297.48 Million INR | 108.63% |
| 2020 | 142.59 Million INR | 413.49% |
| 2019 | 27.76 Million INR | 116.76% |
| 2018 | -165.7 Million INR | -181.16% |
| 2017 | -58.93 Million INR | 95.05% |
| 2016 | -1.19 Billion INR | 28.92% |
| 2015 | -1.67 Billion INR | -68.49% |
| 2014 | -994.03 Million INR | -205.98% |
| 2013 | -324.87 Million INR | -88.1% |
| 2012 | -172.71 Million INR | 0.0% |
| 2010 | 1.16 Billion INR | 43.3% |
| 2009 | 813.14 Million INR | 5.18% |
| 2008 | 773.07 Million INR | 10.92% |
| 2007 | 696.97 Million INR | 46.83% |
| 2006 | 474.69 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -21.49 Million INR | 296.98% |
| 2023 Q4 | 76.11 Million INR | 432.47% |
| 2023 Q1 | 173.07 Million INR | 147.41% |
| 2023 Q2 | 75.59 Million INR | -56.32% |
| 2023 Q3 | -22.89 Million INR | -130.28% |
| 2023 FY | 214.06 Million INR | 33.65% |
| 2022 Q3 | 138.06 Million INR | 188.2% |
| 2022 FY | 160.17 Million INR | -46.16% |
| 2022 Q4 | 69.95 Million INR | -49.33% |
| 2022 Q1 | -3.73 Million INR | -110.18% |
| 2022 Q2 | 47.9 Million INR | 1384.34% |
| 2021 Q4 | 36.62 Million INR | -46.6% |
| 2021 Q1 | 88.64 Million INR | 133.78% |
| 2021 FY | 297.48 Million INR | 108.63% |
| 2021 Q2 | 47.41 Million INR | -46.52% |
| 2021 Q3 | 68.58 Million INR | 44.67% |
| 2020 Q4 | 37.91 Million INR | -64.58% |
| 2020 FY | 142.59 Million INR | 413.49% |
| 2020 Q2 | 89.09 Million INR | 103.97% |
| 2020 Q3 | 107.05 Million INR | 20.16% |
| 2020 Q1 | 43.67 Million INR | -33.71% |
| 2019 Q2 | 2.54 Million INR | 115.59% |
| 2019 Q4 | 65.88 Million INR | -5.4% |
| 2019 Q3 | 69.64 Million INR | 2637.66% |
| 2019 FY | 27.76 Million INR | 116.76% |
| 2019 Q1 | -16.32 Million INR | 79.67% |
| 2018 FY | -165.7 Million INR | -181.16% |
| 2018 Q4 | -80.28 Million INR | -3.46% |
| 2018 Q2 | -41.75 Million INR | -160.82% |
| 2018 Q1 | 68.65 Million INR | -4.12% |
| 2018 Q3 | -77.6 Million INR | -85.85% |
| 2017 Q3 | 9.14 Million INR | 0.0% |
| 2017 Q1 | -115.24 Million INR | 85.87% |
| 2017 FY | -58.93 Million INR | 95.05% |
| 2017 Q4 | 71.6 Million INR | 683.22% |
| 2016 Q3 | -1.82 Billion INR | -183.51% |
| 2016 FY | -1.19 Billion INR | 28.92% |
| 2016 Q1 | -200.26 Million INR | 82.78% |
| 2016 Q2 | -642.36 Million INR | -220.75% |
| 2016 Q4 | -815.83 Million INR | 55.2% |
| 2015 Q2 | -165.99 Million INR | 30.51% |
| 2015 Q4 | -1.16 Billion INR | -435.03% |
| 2015 FY | -1.67 Billion INR | -68.49% |
| 2015 Q3 | -217.41 Million INR | -30.98% |
| 2015 Q1 | -238.85 Million INR | 45.61% |
| 2014 Q3 | -416.97 Million INR | -131.53% |
| 2014 Q2 | -180.1 Million INR | -38.16% |
| 2014 Q1 | -130.35 Million INR | -161.77% |
| 2014 FY | -994.03 Million INR | -205.98% |
| 2014 Q4 | -439.19 Million INR | -5.33% |
| 2013 Q3 | -80.27 Million INR | 54.12% |
| 2013 Q4 | -49.79 Million INR | 37.97% |
| 2013 Q2 | -174.97 Million INR | -7.35% |
| 2013 FY | -324.87 Million INR | -88.1% |
| 2013 Q1 | -162.98 Million INR | 6.19% |
| 2012 Q4 | -173.75 Million INR | -16.93% |
| 2012 Q3 | -148.6 Million INR | -630.13% |
| 2012 FY | -172.71 Million INR | 0.0% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q2 | 28.03 Million INR | 0.0% |
| 2010 FY | 1.16 Billion INR | 43.3% |
| 2009 FY | 813.14 Million INR | 5.18% |
| 2008 FY | 773.07 Million INR | 10.92% |
| 2007 FY | 696.97 Million INR | 46.83% |
| 2006 FY | 474.69 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Hester Biosciences Limited | 364.77 Million INR | -236.092% |
| Albert David Limited | 1.33 Billion INR | 8.13% |
| Alembic Limited | 767.77 Million INR | -59.679% |
| Alkem Laboratories Limited | 19.46 Billion INR | 93.701% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 78.709% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -415.846% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| FDC Limited | 3.03 Billion INR | 59.589% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 86.347% |
| Gufic Biosciences Limited | 2.89 Billion INR | 57.635% |
| Hikal Limited | 1.49 Billion INR | 17.952% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 38.977% |
| Innova Captab Limited | 2.53 Billion INR | 51.608% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -472.773% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 76.374% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -489.264% |
| Laurus Labs Limited | 3.94 Billion INR | 68.952% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | 35.69% |
| Lupin Limited | 27.75 Billion INR | 95.583% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -4364.87% |
| Medico Remedies Limited | 277.11 Million INR | -342.398% |
| Morepen Laboratories Limited | 4.17 Billion INR | 70.627% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 68.489% |
| Orchid Pharma Limited | 2.36 Billion INR | 48.076% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 55.996% |
| RPG Life Sciences Limited | 2.29 Billion INR | 46.518% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 131.819% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.825% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 73.393% |
| Themis Medicare Limited | 1.3 Billion INR | 5.92% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -19378.297% |
| Venus Remedies Limited | 534.65 Million INR | -129.302% |
| Wanbury Limited | 1.7 Billion INR | 28.189% |
| Windlas Biotech Limited | 1.29 Billion INR | 5.614% |
| ZIM Laboratories Limited | 1.09 Billion INR | -11.643% |
| Ipca Laboratories Limited | 29.59 Billion INR | 95.858% |
| Aarti Drugs Limited | 7.14 Billion INR | 82.851% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 60.808% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -5835.147% |
| Brooks Laboratories Limited | -72.25 Million INR | 1796.789% |
| Eris Lifesciences Limited | 5.18 Billion INR | 76.341% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 75.194% |
| Sigachi Industries Limited | 1.47 Billion INR | 16.822% |
| Sakar Healthcare Limited | 495.5 Million INR | -147.417% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 98.827% |
| Divi's Laboratories Limited | 18.31 Billion INR | 93.304% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 72.597% |
| Mankind Pharma Limited | 40.86 Billion INR | 97.0% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 5.31 Billion INR | 76.947% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 83.744% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 81.146% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 97.299% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -97.409% |
| Wockhardt Limited | 140 Million INR | -775.689% |
| Bal Pharma Limited | 214.56 Million INR | -471.361% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 98.19% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 0.409% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -122.26% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 83.032% |
| Shilpa Medicare Limited | 3.76 Billion INR | 67.408% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 93.77% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -43207.642% |
| Granules India Limited | 6.52 Billion INR | 81.221% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -391.859% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 95.161% |
| NATCO Pharma Limited | 25.96 Billion INR | 95.278% |
| Suven Life Sciences Limited | -1.22 Billion INR | 200.012% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 76.54% |
| Indoco Remedies Limited | 1.52 Billion INR | 19.577% |
| Alpa Laboratories Limited | 61.51 Million INR | -1892.951% |
| Lasa Supergenerics Limited | -458 Million INR | 367.675% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 129.792% |